Surrozen Shares Are Trading Higher After the Company Announced It Earned a $10 Million Payment as Part of a Collaboration With Boehringer That Is Advancing the Development of SZN-413 for Retinal Vascular Diseases.
Surrozen Shares Are Trading Higher After the Company Announced It Earned a $10 Million Payment as Part of a Collaboration With Boehringer That Is Advancing the Development of SZN-413 for Retinal Vascular Diseases.
Surrozen股票交易较高，因公司宣布其与拜耳合作的一部分，收到1000万美元付款，推动SZN-413用于视网膜血管疾病的研发。
Surrozen Shares Are Trading Higher After the Company Announced It Earned a $10 Million Payment as Part of a Collaboration With Boehringer That Is Advancing the Development of SZN-413 for Retinal Vascular Diseases.
Surrozen股票交易上涨，公司宣布与拜耳合作，获得1000万美元付款，推动SZN-413用于视网膜血管疾病的开发。
资讯热榜
更新时间